Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Correction to: Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers.

Takehara I, Yoshikado T, Ishigame K, Mori D, Furihata KI, Watanabe N, Ando O, Maeda K, Kusuhara H, Sugiyama Y.

Pharm Res. 2019 Feb 21;36(4):55. doi: 10.1007/s11095-019-2585-8.

PMID:
30790061
2.

Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers.

Mori D, Kashihara Y, Yoshikado T, Kimura M, Hirota T, Matsuki S, Maeda K, Irie S, Ieiri I, Sugiyama Y, Kusuhara H.

Drug Metab Pharmacokinet. 2019 Feb;34(1):78-86. doi: 10.1016/j.dmpk.2018.09.003. Epub 2018 Sep 20.

PMID:
30528195
3.

PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.

Yoshikado T, Toshimoto K, Maeda K, Kusuhara H, Kimoto E, Rodrigues AD, Chiba K, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):739-747. doi: 10.1002/psp4.12348. Epub 2018 Sep 30.

4.

Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers.

Takehara I, Yoshikado T, Ishigame K, Mori D, Furihata KI, Watanabe N, Ando O, Maeda K, Sugiyama Y, Kusuhara H.

Pharm Res. 2018 May 10;35(7):138. doi: 10.1007/s11095-018-2416-3. Erratum in: Pharm Res. 2019 Feb 21;36(4):55.

PMID:
29748935
5.

Total hepatocellular disposition profiling of rosuvastatin and pitavastatin in sandwich-cultured human hepatocytes.

Kanda K, Takahashi R, Yoshikado T, Sugiyama Y.

Drug Metab Pharmacokinet. 2018 Jun;33(3):164-172. doi: 10.1016/j.dmpk.2018.04.001. Epub 2018 Apr 9.

6.

Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling.

Yao Y, Toshimoto K, Kim SJ, Yoshikado T, Sugiyama Y.

Drug Metab Dispos. 2018 Jul;46(7):924-933. doi: 10.1124/dmd.117.079210. Epub 2018 Apr 30.

PMID:
29712725
7.

Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics.

Sato M, Toshimoto K, Tomaru A, Yoshikado T, Tanaka Y, Hisaka A, Lee W, Sugiyama Y.

Drug Metab Dispos. 2018 May;46(5):740-748. doi: 10.1124/dmd.117.078972. Epub 2018 Feb 23.

PMID:
29475833
8.

Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin.

Futatsugi A, Toshimoto K, Yoshikado T, Sugiyama Y, Kato Y.

Drug Metab Dispos. 2018 May;46(5):749-757. doi: 10.1124/dmd.117.078816. Epub 2018 Feb 12.

PMID:
29440178
9.

Investigation of Glycochenodeoxycholate Sulfate and Chenodeoxycholate Glucuronide as Surrogate Endogenous Probes for Drug Interaction Studies of OATP1B1 and OATP1B3 in Healthy Japanese Volunteers.

Takehara I, Terashima H, Nakayama T, Yoshikado T, Yoshida M, Furihata K, Watanabe N, Maeda K, Ando O, Sugiyama Y, Kusuhara H.

Pharm Res. 2017 Aug;34(8):1601-1614. doi: 10.1007/s11095-017-2184-5. Epub 2017 May 26.

PMID:
28550384
10.
11.

A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions.

Yoshikado T, Maeda K, Furihata S, Terashima H, Nakayama T, Ishigame K, Tsunemoto K, Kusuhara H, Furihata KI, Sugiyama Y.

Pharm Res. 2017 Aug;34(8):1570-1583. doi: 10.1007/s11095-017-2168-5. Epub 2017 May 8.

PMID:
28484975
12.

Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.

Kim SJ, Toshimoto K, Yao Y, Yoshikado T, Sugiyama Y.

J Pharm Sci. 2017 Sep;106(9):2715-2726. doi: 10.1016/j.xphs.2017.04.063. Epub 2017 May 4.

PMID:
28479356
13.

Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins.

Yoshikado T, Toshimoto K, Nakada T, Ikejiri K, Kusuhara H, Maeda K, Sugiyama Y.

Drug Metab Dispos. 2017 Jul;45(7):779-789. doi: 10.1124/dmd.116.074823. Epub 2017 May 3.

PMID:
28468836
14.

Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP.

Kashihara Y, Ieiri I, Yoshikado T, Maeda K, Fukae M, Kimura M, Hirota T, Matsuki S, Irie S, Izumi N, Kusuhara H, Sugiyama Y.

J Pharm Sci. 2017 Sep;106(9):2688-2694. doi: 10.1016/j.xphs.2017.03.010. Epub 2017 Mar 18.

PMID:
28322941
15.

Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information.

Kim SJ, Yoshikado T, Ieiri I, Maeda K, Kimura M, Irie S, Kusuhara H, Sugiyama Y.

Drug Metab Dispos. 2016 Oct;44(10):1622-32. doi: 10.1124/dmd.116.070276. Epub 2016 Jul 25.

PMID:
27457785
16.

Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.

Yoshikado T, Yoshida K, Kotani N, Nakada T, Asaumi R, Toshimoto K, Maeda K, Kusuhara H, Sugiyama Y.

Clin Pharmacol Ther. 2016 Nov;100(5):513-523. doi: 10.1002/cpt.391. Epub 2016 Jul 28.

PMID:
27170342
17.

[Transporters and molecular-targeted drugs].

Yoshikado T, Sugiyama Y.

Nihon Rinsho. 2012 Nov;70 Suppl 8:688-94. Japanese. No abstract available.

PMID:
23513922
18.

Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites.

Yoshikado T, Takada T, Yamamoto H, Tan JK, Ito K, Santa T, Suzuki H.

Mol Pharmacol. 2013 Feb;83(2):552-62. doi: 10.1124/mol.112.081752. Epub 2012 Dec 6.

PMID:
23220748
19.

Ursodeoxycholic acid stimulates the formation of the bile canalicular network.

Ikebuchi Y, Shimizu H, Ito K, Yoshikado T, Yamanashi Y, Takada T, Suzuki H.

Biochem Pharmacol. 2012 Oct 1;84(7):925-35. doi: 10.1016/j.bcp.2012.07.008. Epub 2012 Jul 20.

PMID:
22820248
20.

NPC2 regulates biliary cholesterol secretion via stimulation of ABCG5/G8-mediated cholesterol transport.

Yamanashi Y, Takada T, Yoshikado T, Shoda J, Suzuki H.

Gastroenterology. 2011 May;140(5):1664-74. doi: 10.1053/j.gastro.2011.01.050. Epub 2011 Mar 21.

PMID:
21315718
21.

Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4.

Yoshikado T, Takada T, Yamamoto T, Yamaji H, Ito K, Santa T, Yokota H, Yatomi Y, Yoshida H, Goto J, Tsuji S, Suzuki H.

Mol Pharmacol. 2011 Feb;79(2):241-50. doi: 10.1124/mol.110.067256. Epub 2010 Nov 5.

PMID:
21056966
22.

Compounds having thiourea moiety as derivatization reagents in liquid chromatography/electrospray ionization-tandem mass spectrometry (LC/ESI-MS/MS): synthesis of derivatization reagents for carboxylic acids.

Inoda H, Nishiyama T, Yoshikado T, Suwanai Y, Santa T.

Biomed Chromatogr. 2011 Jun;25(6):635-40. doi: 10.1002/bmc.1501. Epub 2010 Sep 1.

PMID:
20812201
23.

Receptor for activated C-kinase 1 regulates the cellular localization and function of ABCB4.

Ikebuchi Y, Takada T, Ito K, Yoshikado T, Anzai N, Kanai Y, Suzuki H.

Hepatol Res. 2009 Nov;39(11):1091-107. doi: 10.1111/j.1872-034X.2009.00544.x. Epub 2009 Aug 6.

PMID:
19674157
24.

Synthesis of benzofurazan derivatization reagents for short chain carboxylic acids in liquid chromatography/electrospray ionization-tandem mass spectrometry (LC/ESI-MS/MS).

Santa T, Al-Dirbashi OY, Yoshikado T, Fukushima T, Imai K.

Biomed Chromatogr. 2009 Apr;23(4):443-6. doi: 10.1002/bmc.1124.

PMID:
19016225

Supplemental Content

Loading ...
Support Center